-
公开(公告)号：US20240117058A1
公开(公告)日：2024-04-11
申请号：US18485116
申请日：2023-10-11
发明人： Joe Pirrello , John Paolini , Eben Tessari
IPC分类号： C07K16/28 , A61K31/573 , A61K31/685 , A61P31/14
CPC分类号： C07K16/2866 , A61K31/573 , A61K31/685 , A61P31/14 , A61K2039/545
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
公开(公告)号：US20210054085A1
公开(公告)日：2021-02-25
申请号：US17050261
申请日：2019-04-25
发明人： John Paolini , Rohan Gandhi , Zamaneh Mikhak
摘要： The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.
-
公开(公告)号：US20240101690A1
公开(公告)日：2024-03-28
申请号：US18193393
申请日：2023-03-30
发明人： John Paolini , Rohan Gandhi , Zamaneh Mikhak
IPC分类号： C07K16/28 , A61K39/395 , A61P17/04 , G01N33/53
CPC分类号： C07K16/2866 , A61K39/3955 , A61P17/04 , G01N33/53 , A61P17/00
摘要： The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or in disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, in associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.
-
公开(公告)号：US11325979B2
公开(公告)日：2022-05-10
申请号：US17324931
申请日：2021-05-19
发明人： Joe Pirrello , John Paolini , Eben Tessari
IPC分类号： C07K16/28 , A61P31/14 , A61K31/573 , A61K31/685 , A61K39/00
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
公开(公告)号：US20210284745A1
公开(公告)日：2021-09-16
申请号：US17324931
申请日：2021-05-19
发明人： Joe Pirrello , John Paolini , Eben Tessari
IPC分类号： C07K16/28 , A61K31/685 , A61K31/573 , A61P31/14
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
公开(公告)号：US20210284744A1
公开(公告)日：2021-09-16
申请号：US17201698
申请日：2021-03-15
发明人： Joe Pirrello , John Paolini , Eben Tessari
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
